Clinical Trials Browser

Phase 1/2 × Lymphoma, Non-Hodgkin × Dasatinib × Clear all

NCT00550615 2023-09-26

Dasatinib in Relapsed or Refractory Non-Hodgkin's Lymphoma

Phase 1/2 Completed

38 enrolled 9 charts

Lymphoma, Non-Hodgkin